Simon Amy sold $13K of BEAM
Simon Amy (Chief Medical Officer) sold 373 shares of Beam Therapeutics Inc. (BEAM) at $34.73 on 2026-06-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; it does not include new clinical, regulatory, or financial guidance.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 structure typically reduces interpretive weight versus unscheduled selling.
What to watch
The article provides no information on whether the sale was part of a broader pattern, nor any change in company outlook; without that, the signal quality is low.
Background
This is an SEC Form 4 insider transaction disclosure for Beam Therapeutics, reported via EDGAR.
Ticker impact
Beam Therapeutics disclosed a Form 4 showing CMO Simon Amy sold 373 shares on June 30 under a 10b5-1 plan.
Likely negligible near-term price impact; any effect would be sentiment-driven and short-lived.
The filing is a scheduled open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes disclosed.
Market effects
No clear read-through to biotech sector fundamentals from a single routine 10b5-1 sale.
None.
None.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with internal risk management or diversification needs, which some traders may still fade.
Key entities
- issuerBeam Therapeutics Inc.
Company whose insider transaction was disclosed on Form 4.
- insiderSimon Amy
Chief Medical Officer who sold shares under a 10b5-1 plan.
